FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102076191> ?p ?o ?g. }

• W2102076191 endingPage "1760" @default.
• W2102076191 startingPage "1753" @default.
• W2102076191 abstract "Background Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes might improve β-cell function and result in extended glycaemic remissions. We did a multicentre, randomised trial to compare the effects of transient intensive insulin therapy (continuous subcutaneous insulin infusion [CSII] or multiple daily insulin injections [MDI]) with oral hypoglycaemic agents on β-cell function and diabetes remission rate. Methods 382 patients, aged 25–70 years, were enrolled from nine centres in China between September, 2004, and October, 2006. The patients, with fasting plasma glucose of 7·0–16·7 mmol/L, were randomly assigned to therapy with insulin (CSII or MDI) or oral hypoglycaemic agents for initial rapid correction of hyperglycaemia. Treatment was stopped after normoglycaemia was maintained for 2 weeks. Patients were then followed-up on diet and exercise alone. Intravenous glucose tolerance tests were done and blood glucose, insulin, and proinsulin were measured before and after therapy withdrawal and at 1-year follow-up. Primary endpoint was time of glycaemic remission and remission rate at 1 year after short-term intensive therapy. Analysis was per protocol. This study was registered with ClinicalTrials.gov, number NCT00147836. Findings More patients achieved target glycaemic control in the insulin groups (97·1% [133 of 137] in CSII and 95·2% [118 of 124] in MDI) in less time (4·0 days [SD 2·5] in CSII and 5·6 days [SD 3·8] in MDI) than those treated with oral hypoglycaemic agents (83·5% [101 of 121] and 9·3 days [SD 5·3]). Remission rates after 1 year were significantly higher in the insulin groups (51·1% in CSII and 44·9% in MDI) than in the oral hypoglycaemic agents group (26·7%; p=0.0012). β-cell function represented by HOMA B and acute insulin response improved significantly after intensive interventions. The increase in acute insulin response was sustained in the insulin groups but significantly declined in the oral hypoglycaemic agents group at 1 year in all patients in the remission group. Interpretation Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favourable outcomes on recovery and maintenance of β-cell function and protracted glycaemic remission compared with treatment with oral hypoglycaemic agents. Funding 973 Programme from the Chinese Government, the Natural Science Foundation of Guangdong Province Government, Novo Nordisk (China), and Roche Diagnostics (Shanghai). Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes might improve β-cell function and result in extended glycaemic remissions. We did a multicentre, randomised trial to compare the effects of transient intensive insulin therapy (continuous subcutaneous insulin infusion [CSII] or multiple daily insulin injections [MDI]) with oral hypoglycaemic agents on β-cell function and diabetes remission rate. 382 patients, aged 25–70 years, were enrolled from nine centres in China between September, 2004, and October, 2006. The patients, with fasting plasma glucose of 7·0–16·7 mmol/L, were randomly assigned to therapy with insulin (CSII or MDI) or oral hypoglycaemic agents for initial rapid correction of hyperglycaemia. Treatment was stopped after normoglycaemia was maintained for 2 weeks. Patients were then followed-up on diet and exercise alone. Intravenous glucose tolerance tests were done and blood glucose, insulin, and proinsulin were measured before and after therapy withdrawal and at 1-year follow-up. Primary endpoint was time of glycaemic remission and remission rate at 1 year after short-term intensive therapy. Analysis was per protocol. This study was registered with ClinicalTrials.gov, number NCT00147836. More patients achieved target glycaemic control in the insulin groups (97·1% [133 of 137] in CSII and 95·2% [118 of 124] in MDI) in less time (4·0 days [SD 2·5] in CSII and 5·6 days [SD 3·8] in MDI) than those treated with oral hypoglycaemic agents (83·5% [101 of 121] and 9·3 days [SD 5·3]). Remission rates after 1 year were significantly higher in the insulin groups (51·1% in CSII and 44·9% in MDI) than in the oral hypoglycaemic agents group (26·7%; p=0.0012). β-cell function represented by HOMA B and acute insulin response improved significantly after intensive interventions. The increase in acute insulin response was sustained in the insulin groups but significantly declined in the oral hypoglycaemic agents group at 1 year in all patients in the remission group. Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favourable outcomes on recovery and maintenance of β-cell function and protracted glycaemic remission compared with treatment with oral hypoglycaemic agents." @default.
• W2102076191 created "2016-06-24" @default.
• W2102076191 creator A5012775407 @default.
• W2102076191 creator A5014201221 @default.
• W2102076191 creator A5021384155 @default.
• W2102076191 creator A5024058852 @default.
• W2102076191 creator A5024741363 @default.
• W2102076191 creator A5035863523 @default.
• W2102076191 creator A5036245477 @default.
• W2102076191 creator A5037330078 @default.
• W2102076191 creator A5038389607 @default.
• W2102076191 creator A5040785271 @default.
• W2102076191 creator A5040985281 @default.
• W2102076191 creator A5047585547 @default.
• W2102076191 creator A5051992470 @default.
• W2102076191 creator A5058514032 @default.
• W2102076191 creator A5061894086 @default.
• W2102076191 creator A5063227916 @default.
• W2102076191 creator A5063727121 @default.
• W2102076191 creator A5065388588 @default.
• W2102076191 creator A5080125836 @default.
• W2102076191 creator A5081066035 @default.
• W2102076191 creator A5083822183 @default.
• W2102076191 creator A5084579042 @default.
• W2102076191 creator A5085639572 @default.
• W2102076191 date "2008-05-01" @default.
• W2102076191 modified "2023-10-11" @default.
• W2102076191 title "Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial" @default.
• W2102076191 cites W1598254642 @default.
• W2102076191 cites W1964921050 @default.
• W2102076191 cites W1967005515 @default.
• W2102076191 cites W1967943195 @default.
• W2102076191 cites W1983099475 @default.
• W2102076191 cites W2002362232 @default.
• W2102076191 cites W2014317180 @default.
• W2102076191 cites W2016089130 @default.
• W2102076191 cites W2040536132 @default.
• W2102076191 cites W2063392732 @default.
• W2102076191 cites W2094434238 @default.
• W2102076191 cites W2111236186 @default.
• W2102076191 cites W2112535191 @default.
• W2102076191 cites W2146975696 @default.
• W2102076191 cites W2150159032 @default.
• W2102076191 cites W2159859567 @default.
• W2102076191 cites W2160234571 @default.
• W2102076191 cites W2188846692 @default.
• W2102076191 cites W2337454357 @default.
• W2102076191 doi "https://doi.org/10.1016/s0140-6736(08)60762-x" @default.
• W2102076191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18502299" @default.
• W2102076191 hasPublicationYear "2008" @default.
• W2102076191 type Work @default.
• W2102076191 sameAs 2102076191 @default.
• W2102076191 citedByCount "664" @default.
• W2102076191 countsByYear W21020761912012 @default.
• W2102076191 countsByYear W21020761912013 @default.
• W2102076191 countsByYear W21020761912014 @default.
• W2102076191 countsByYear W21020761912015 @default.
• W2102076191 countsByYear W21020761912016 @default.
• W2102076191 countsByYear W21020761912017 @default.
• W2102076191 countsByYear W21020761912018 @default.
• W2102076191 countsByYear W21020761912019 @default.
• W2102076191 countsByYear W21020761912020 @default.
• W2102076191 countsByYear W21020761912021 @default.
• W2102076191 countsByYear W21020761912022 @default.
• W2102076191 countsByYear W21020761912023 @default.
• W2102076191 crossrefType "journal-article" @default.
• W2102076191 hasAuthorship W2102076191A5012775407 @default.
• W2102076191 hasAuthorship W2102076191A5014201221 @default.
• W2102076191 hasAuthorship W2102076191A5021384155 @default.
• W2102076191 hasAuthorship W2102076191A5024058852 @default.
• W2102076191 hasAuthorship W2102076191A5024741363 @default.
• W2102076191 hasAuthorship W2102076191A5035863523 @default.
• W2102076191 hasAuthorship W2102076191A5036245477 @default.
• W2102076191 hasAuthorship W2102076191A5037330078 @default.
• W2102076191 hasAuthorship W2102076191A5038389607 @default.
• W2102076191 hasAuthorship W2102076191A5040785271 @default.
• W2102076191 hasAuthorship W2102076191A5040985281 @default.
• W2102076191 hasAuthorship W2102076191A5047585547 @default.
• W2102076191 hasAuthorship W2102076191A5051992470 @default.
• W2102076191 hasAuthorship W2102076191A5058514032 @default.
• W2102076191 hasAuthorship W2102076191A5061894086 @default.
• W2102076191 hasAuthorship W2102076191A5063227916 @default.
• W2102076191 hasAuthorship W2102076191A5063727121 @default.
• W2102076191 hasAuthorship W2102076191A5065388588 @default.
• W2102076191 hasAuthorship W2102076191A5080125836 @default.
• W2102076191 hasAuthorship W2102076191A5081066035 @default.
• W2102076191 hasAuthorship W2102076191A5083822183 @default.
• W2102076191 hasAuthorship W2102076191A5084579042 @default.
• W2102076191 hasAuthorship W2102076191A5085639572 @default.
• W2102076191 hasConcept C126322002 @default.
• W2102076191 hasConcept C134018914 @default.
• W2102076191 hasConcept C141071460 @default.
• W2102076191 hasConcept C168563851 @default.
• W2102076191 hasConcept C203092338 @default.
• W2102076191 hasConcept C2777180221 @default.
• W2102076191 hasConcept C2779306644 @default.
• W2102076191 hasConcept C2781232474 @default.
• W2102076191 hasConcept C555293320 @default.

• next